Home › Traumatic Brain Injury › NCT04121780
Growth Hormone Replacement Therapy for Retried Professional Football Players
RecruitingPhase 2
Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency
Who can join
Ages 18 to 76 · Men
Full eligibility criteria
Inclusion Criteria: * The subject is willing to provide a signed and dated informed consent indicating that he understands the purpose and procedures required for the study and is willing to participate in the study. * Former NFL player * At least one year since retirement from football * Less than 76 years of age * Diagnosis of GHD on clinical grounds by a neurologist and an endocrinologist GHD Exclusion Criteria: * History of pre-existing brain disease other than concussion or TBI * History of a premorbid disabling condition that interferes with outcome assessments * Contraindication to GH therapy * Type I and II Diabetes mellitus * Active malignant disease * Acute critical illness, heart failure, or acute respiratory failure * Subjects who are deficient in cortisol, testosterone or thyroid at screening will be excluded until hormone abnormalities have been corrected.
About the study
This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).
What is being tested
- Growth Hormone (biological)
- Placebo (other)
Sponsor: Center for Neurological Studies · Participants: 42 · Started: Oct 8, 2019
Contact the study team
- Vijay M Baragi, Ph.D. · Phone: 313-228-0930.
- John Russell · Phone: 3132280930
Official record on ClinicalTrials.gov — NCT04121780
Locations in the U.S.
| Michigan | Center for Neurolgoical Studies (CNS), Dearborn |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.